<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>In vivo effects of rosiglitazone in a human neuroblastoma xenograft.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="In vivo effects of rosiglitazone in a human neuroblastoma xenograft." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e20/2837558/c1f80f144b7b/6605506f6.jpg"/> </div> <div class="text-side"> <h1>In vivo effects of rosiglitazone in a human neuroblastoma xenograft.</h1> <p>Immunohistochemistry (IHC) for CD-31 evaluation in tumour tissues from control (i.e., solvent treated) and rosiglitazone (RGZ)-treated (A, 2 weeks; B, 4 weeks) mice. Y axis: number of CD-31-positive cells per field. (C) Example of a field showing high CD-31 staining in the tissue sample from a control mouse. (D) Example of a field showing a few CD-31-positive cells after 4 weeks of treatment with RGZ ( Ã— 100 magnification).</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/20068562/" target="_blank">20068562</a></p><p>Type: Premalignant/Malignant, Category: Neural or neuroendocrine</p>
</div> </div></div></body></html>